Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2016-07-18

FDA Approved: VELETRI — Supplemental Application (Actelion Pharmaceuticals US, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for VELETRI (epoprostenol) from Actelion Pharmaceuticals US, Inc., leading to changes to its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • VELETRI (EPOPROSTENOL)

Snippet

SUPPL AP for VELETRI (EPOPROSTENOL)